Metyrapone

Modify Date: 2024-01-22 16:42:47

Metyrapone Structure
Metyrapone structure
Common Name Metyrapone
CAS Number 908-35-0 Molecular Weight 376.361
Density N/A Boiling Point N/A
Molecular Formula C18H20N2O7 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Metyrapone


Metyrapone (Su-4885) Tartrate is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone Tartrate inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone Tartrate increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone Tartrate can be used for researching Cushing's syndrome and depression[1][2][3][4][5].

 Names

Name Metyrapone tartrate
Synonym More Synonyms

 Metyrapone Biological Activity

Description Metyrapone (Su-4885) Tartrate is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone Tartrate inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone Tartrate increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone Tartrate can be used for researching Cushing's syndrome and depression[1][2][3][4][5].
Related Catalog
Target

11β-hydroxylase, Aldosterone, CYP450, Autophagy[1][4][5]

In Vitro Metyrapone (100 μM; 2 h) hyperactivates autophagy in HepG2, and delays the activation of apoptosis at severe endoplasmic reticulum (ER) stress[5].
In Vivo Metyrapone (25 or 50 mg/kg; SC, single dosage) decreases the stress-induced increase in plasma corticosterone levels, significantly impairs acquisition performance at high dosage, and increases open arm activity at low dosage[1]. Animal Model: Male Sprague-Dawley rats (n=179; 270-300g)[1] Dosage: 25 or 50 mg/kg (in a volume of 2.0 ml/kg) Administration: SC, single dosage Result: Dose-dependently decreased the stress-induced increase in plasma corticosterone levels in the water maze test; the high level dose significantly impaired acquisition performance in the water maze and decreased fear-induced immobility; the lower dose increased open arm activity.
References

[1]. Roozendaal B, et al. Dose-dependent suppression of adrenocortical activity with metyrapone: effects on emotion and memory. Psychoneuroendocrinology. 1996 Nov;21(8):681-93.

[2]. Jahn H, et al. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry. 2004 Dec;61(12):1235-44.

[3]. Daniel E, et al. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. J Clin Endocrinol Metab. 2015 Nov;100(11):4146-54.

[4]. Peterson JA, Ullrich V, Hildebrandt AG. Methyrapone interaction with Pseudomonas putida cytochrome P-405. Arch Biochem Biophys. 1971 Aug;145(2):531-42.

[5]. Holczer M, et al. A Comprehensive Systems Biological Study of Autophagy-Apoptosis Crosstalk during Endoplasmic Reticulum Stress. Biomed Res Int. 2015;2015:319589.

 Chemical & Physical Properties

Molecular Formula C18H20N2O7
Molecular Weight 376.361
Exact Mass 376.127045

 Synonyms

Metopirone ditartrate
Butanedioic acid, 2,3-dihydroxy-, (2R,3R)-, compd. with 2-methyl-1,2-di-3-pyridinyl-1-propanone (1:1)
2-Methyl-1,2-di-3-pyridinyl-1-propanone (R-(R*,R*))-2,3-Dihydroxybutanedioate (1:2)
(2R,3R)-2,3-Dihydroxysuccinic acid - 2-methyl-1,2-di(3-pyridinyl)-1-propanone (1:1)
Metyrapone tartrate